The #1 Longevity Community
Canvas introduces EMR system for longevity medicine
Anova aims to help longevity clinicians keep up with rapidly evolving scientific developments with real-time updates on clinical protocols.
MedTech company Canvas Medical today launched Anova, a new electronic medical record (EMR) system specifically designed for longevity medicine. Developed in collaboration with longevity physicians, Anova offers an all-in-one platform designed to address the specific demands of the emerging longevity specialty.
Leveraging the capabilities of Canvas’s c
Cytomos raises £5m to advance scalable cell-analysis tech for drug discovery
New investment enables the scale-up of Celledonia platform to transform biologics development and manufacturing.
Cytomos, an Edinburgh-based biotech, has secured £5 million in funding to scale up production of its innovative cell-analysis platform, AuraCyt, and its first commercial product, Celledonia. The funding round was oversubscribed and led by Archangels, a prominent early-stage investor in Scottish life sciences and technology, with additional contributions from Old College Capital, S
Intranasal Spray Alleviates Early Alzheimer’s in Mice
<div><p style="text-align: justify;">A novel therapy based on induced neuronal stem cells <a href="https://doi.org/10.1002/jev2.12519">shows promise in a mouse model of Alzheimer’s disease</a> – and it can be administered intranasally [1].</p>
<h2 style="text-align: justify;"><b>Who needs cells?</b></h2>
<p style="text-align: justify;">Stem cell therapies have made great strides in recent decades. They have been successfully employed against numerous diseases, from cancer to osteoarthritis. However, storing, transporting, and administering cells is not easy. Moreover, in some cases, cells, with their extraordinarily complex metabolisms, can produce unwanted side effects. For instance, neural stem/progenitor cells (NSCs) have been shown to improve symptoms of certain brain diseases [2] but can also trigger pathological changes in the brain [3].</p>
<p style="text-align: justify;">However, the whole cell might not always be necessary. Cells have been known to communicate with each other by excreting extracellular vesicles (EVs), tiny membrane-bound bubbles that can carry various cargoes, such as RNA molecules and proteins. Scientists have learned to harvest vesicles produced by cells and administer them locally or systemically, often recapitulating much of the effect of cell administration.</p>
<p style="text-align: justify;">Unlike stem cells, EVs can be frozen and thawed without compromising their therapeutic efficacy. Furthermore, cells of different types can now be easily produced from induced pluripotent stem cells (iPSCs). Those are somatic cells reverted into pluripotency by applying certain molecules, such as the original reprogramming cocktail of Yamanaka factors (OSKM).</p>
<h2 style="text-align: justify;"><b>Less inflammation</b></h2>
<p style="text-align: justify;">In a new study published in the <i>Journal of Extracellular Vesicles</i>, researchers from Texas A&M University took human iPSCs and re-differentiated them into NSCs. They then harvested the extracellular vesicles produced by the cells, purified them, and administered them intranasally to a mouse model of familial Alzheimer’s disease (5xFAD mice). Despite decades of research and tens of billions of dollars spent, a cure for Alzheimer’s remains elusive.</p>
<p style="text-align: justify;">While mouse models of Alzheimer’s have their limitations, as mice naturally don’t develop this disease, 5xFAD mice have been widely used. These animals start displaying Alzheimer’s-like pathologies, such as amyloid beta (Aβ) plaques and increased neuroinflammation at the age of three months, which is when the treatment was administered. About two months later, the mice underwent cognitive and neuropathological assessments.</p>
<p style="text-align: justify;">The researchers confirmed that the EVs were indeed taken up by the brain’s resident macrophages (microglia). In Alzheimer’s, these cells surround Aβ plaques, presumably in an attempt to remove them. They display increased activation and inflammation, which has been linked to disease progression.</p>
<p style="text-align: justify;">“Prolonged activation causes microglia to lose their normal function and begin to harm neurons, leading to progressive neuron loss,” explains Ashok K. Shetty, Ph.D., a University Distinguished Professor and associate director at the Institute for Regenerative Medicine in the Department of Cell Biology and Genetics, and the corresponding author on the study.</p>
<p style="text-align: justify;">RNA sequencing revealed that the treatment downregulated multiple inflammation-related pathways that were significantly upregulated in 5xFAD mice compared to healthy controls. Notably, this occurred without compromising the microglia’s phagocytosis function: their ability to engulf and destroy pathogens.</p>
<p style="text-align: justify;">The treatment also led to a significant reduction in the burden of Aβ plaques and phosphorylated tau protein, two major hallmarks of Alzheimer’s. While both sexes showed improvements, males demonstrated a more robust response to the treatment.</p>
<p><img fetchpriority="high" decoding="async" class="aligncenter wp-image-133844 size-full" src="https://www.lifespan.io/wp-content/uploads/2024/11/EVs-Alzheimers-Mice.png" alt="EVs Alzheimer's Mice" width="1000" height="491" srcset="https://www.lifespan.io/wp-content/uploads/2024/11/EVs-Alzheimers-Mice.png 1000w, https://www.lifespan.io/wp-content/uploads/2024/11/EVs-Alzheimers-Mice-400x196.png 400w, https://www.lifespan.io/wp-content/uploads/2024/11/EVs-Alzheimers-Mice-745x366.png 745w, https://www.lifespan.io/wp-content/uploads/2024/11/EVs-Alzheimers-Mice-256x126.png 256w, https://www.lifespan.io/wp-content/uploads/2024/11/EVs-Alzheimers-Mice-300x147.png 300w, https://www.lifespan.io/wp-content/uploads/2024/11/EVs-Alzheimers-Mice-150x74.png 150w, https://www.lifespan.io/wp-content/uploads/2024/11/EVs-Alzheimers-Mice-480x236.png 480w, https://www.lifespan.io/wp-content/uploads/2024/11/EVs-Alzheimers-Mice-600x295.png 600w, https://www.lifespan.io/wp-content/uploads/2024/11/EVs-Alzheimers-Mice-360x177.png 360w, https://www.lifespan.io/wp-content/uploads/2024/11/EVs-Alzheimers-Mice-262x129.png 262w, https://www.lifespan.io/wp-content/uploads/2024/11/EVs-Alzheimers-Mice-555x273.png 555w" sizes="(max-width: 1000px) 100vw, 1000px"></p>
<p style="text-align: justify;">By the age of five months, 5xFAD mice typically demonstrate significant cognitive decline, which was also observed in this study. The EV treatment, however, appeared to effectively block this decline. Tests included the object location test, in which cognitively healthy animals are expected to spend more time exploring an object in a novel place than in a familiar place, and the pattern recognition test, which measures the ability to discern novel objects from familiar ones.</p>
<p style="text-align: justify;">Interestingly, the researchers also assessed the mice’s mood. Mood changes are increasingly gaining recognition as a clinically important aspect of Alzheimer’s disease. Just like many human Alzheimer’s patients, untreated 5xFAD mice exhibited anhedonia, the inability to enjoy things – in this case, sweetened water. The EV treatment restored the rodents’ joie de vivre – or at least their preference for sugar.</p>
<h2 style="text-align: justify;"><b>Similar effects in human cells</b></h2>
<p style="text-align: justify;">While the researchers did not test their treatment in human patients, they pursued the next best alternative: applying NSC-derived EVs to human microglia in vitro. When challenged with Aβ-42, an isoform of Aβ known for its high aggregation propensity and central role in the pathology of Alzheimer’s disease, microglia exhibited overactivation and an inflammatory phenotype. These effects, however, were reversed by the EV treatment.</p>
<p style="text-align: justify;">According to the paper, EVs are superior to NSCs in that they do not replicate and readily cross the blood-brain barrier. Intranasal administration is easy, non-invasive, and characterized by rapid action. While the study was conducted on animals at early stages of the disease, constant advances in diagnostics make this less of a limitation.</p>
<p style="text-align: justify;">“This approach is effective because the cargo carried by these extracellular vesicles could reduce the neuropathological changes in the brain,” says Shetty, who has filed a patent on the intranasal application of neural stem cell-derived extracellular vesicles for treating Alzheimer’s and other neurological disorders. “Our journey to advance the application of this therapy for Alzheimer’s disease is just beginning.”</p>
<div class="textwidget"><div class="sep-2"></div>
<div class="life-highlight-box lhbox-has-zoom-yes l-hbox-size-large l-hbox-edges-square" style="background-color: #cef0f5;"><div class="l-hbox-lower"><div class="l-hbox-lower-desc" style="color:#000;">We would like to ask you a small favor. <strong>We are a non-profit foundation</strong>, and unlike some other organizations, we have no shareholders and no products to sell you. <strong>All our news and educational content is free</strong> for everyone to read, but it does mean that we rely on the help of people like you. Every contribution, no matter if it’s big or small, <strong>supports independent journalism</strong> and sustains our future. </div><style>.rb--fec6b22d105305 a {background-color:#1e4fba;}.rb--fec6b22d105305 a:hover {background-color:#79bcf0;}</style><div class="l-hbox-lower-cta rb--fec6b22d105305"><a href="https://www.lifespan.io/how-you-can-help/" target="_self" rel="noopener">Yes I will donate❤️</a></div></div></div>
</div>
<h2 style="text-align: justify;"><b>Literature</b></h2>
<p style="text-align: justify;">[1] Madhu, L. N., Kodali, M., Upadhya, R., Rao, S., Somayaji, Y., Attaluri, S., … & Shetty, A. K. (2024). Extracellular vesicles from human‐induced pluripotent stem cell‐derived neural stem cells alleviate proinflammatory cascades within disease‐associated microglia in Alzheimer’s disease. Journal of Extracellular Vesicles, 13(11), e12519.</p>
<p style="text-align: justify;">[2] Temple, S. (2023). Advancing cell therapy for neurodegenerative diseases. Cell stem cell, 30(5), 512-529.</p>
<p style="text-align: justify;">[3] Abdi, S., Javanmehr, N., Ghasemi-Kasman, M., Bali, H. Y., & Pirzadeh, M. (2022). Stem cell-based therapeutic and diagnostic approaches in Alzheimer’s disease. Current Neuropharmacology, 20(6), 1093-1115.</p>
<div id="playht-shortcode" data-shortcode='
<div
id="playht-iframe-wrapper"
style="display:flex; max-height:"90px"; justify-content:center">
<iframe
allowfullscreen=""
frameborder="0"
scrolling="no"
class="playht-iframe-player"
data-appId="E9FaMfn-qe"
article-url="https://www.lifespan.io/?p=133835"
data-voice="en-US-BrandonNeural"
src="https://play.ht/embed/?article_url=https://www.lifespan.io/?p=133835&voice=en-US-BrandonNeural&config={"width":""100%"","height":""90px"","alignment":"center","title":"Audio","message":"Hello","download_text_button":"Download"}"
width=""100%""
height=""90px""
style="max-height:"90px"">
</iframe>
</div>'></div></div>
New clinic guidelines to set global standards in longevity medicine
<div><img width="525" height="350" src="https://longevity.technology/wp-content/uploads/2024/11/abu-dhabi-skyline-at-blue-hour-modern-high-rise-b-2023-11-27-04-49-41-utc-vinnikava-Envato-1024x683.jpg" class="webfeedsFeaturedVisual wp-post-image" alt="" style="display: block; margin-bottom: 5px; clear:both;max-width: 100%;" link_thumbnail="" decoding="async" sizes="(max-width: 767px) 89vw, (max-width: 1000px) 54vw, (max-width: 1071px) 543px, 580px">
<h2 class="wp-block-heading"><strong>Abu Dhabi partners with IHLAD and HLMS to establish standards for longevity clinics and licenses IHLAD as healthy longevity medicine center.</strong></h2>
<p>Abu Dhabi has taken a significant step in advancing healthcare by establishing the world’s first evidence-based clinical guidelines for healthy longevity medicine. Through collaboration with the <a href="https://www.doh.gov.ae/en/" target="_blank" rel="noreferrer noopener">Department of Health Abu Dhabi (DOH)</a>, the <a href="https://www.ihlad.ae/" target="_blank" rel="noreferrer noopener">Institute for Healthier Living Abu Dhabi (IHLAD)</a>, and the <a href="https://hlms.co/" target="_blank" rel="noreferrer noopener">Healthy Longevity Medicine Society (HLMS)</a>, this initiative aims to transform healthcare provision by integrating preventive and longevity-focused care. This framework sets a new benchmark, particularly in the Middle East, for clinical guidelines that support healthy aging and enhance quality of life.</p>
<p>In addition, the DoH has <a href="https://www.mediaoffice.abudhabi/en/health/department-of-health-abu-dhabi-licenses-institute-for-healthier-living-abu-dhabi-as-worlds-first-specialised-healthy-longevity-medicine-centre/" target="_blank" rel="noreferrer noopener">announced the licensing of IHLAD</a> as the first specialised healthy longevity medicine center (HLMC) in the world. In <a href="https://www.mediaoffice.abudhabi/en/health/department-of-health-abu-dhabi-licenses-institute-for-healthier-living-abu-dhabi-as-worlds-first-specialised-healthy-longevity-medicine-centre/" target="_blank" rel="noreferrer noopener">a statement</a>, DoH said that “as the world’s first regulated longevity medicine facility, it will contribute to establishing new global standards in healthy longevity medicine, promising a future where optimal health and enhanced longevity becomes the new standard of living.”</p>
<p>The HLMCs will be equipped to address various aspects of care, including lifestyle, medications and therapeutics, mental well-being, social and environmental factors. This includes diagnostic and interventional services designed to prevent and treat age-related conditions, enhance physical fitness and improve rehabilitation outcomes.</p>
<p><em style=""><b>Longevity.Technology: </b></em><strong><em>As longevity science advances, the focus within longevity medicine is increasingly on clinical standards, prioritizing disease prevention and extended healthspan. This rapid development signals an urgent need for healthcare systems to adapt, centering on prevention and promoting healthy aging. Establishing standards and fostering global collaboration will be essential for the implementation of best practices, and to ensure that the benefits of longevity science reach as many as possible. Next month’s <a href="https://longevity-roundtable.com/" target="_blank" rel="noreferrer noopener">Roundtable on Longevity Clinics</a> will also focus on standardizing clinical practices across the field, underscoring a growing commitment to integrating longevity-focused practices into mainstream clinical care.</em></strong></p>
<p>The guidelines, effective from April 2025, set licensing criteria for facilities in Abu Dhabi and establish comprehensive standards for what constitutes a ‘Healthy Longevity Clinic’; this covers aspects such as advanced diagnostics, personalized interventions and rigorous clinical governance. This structure is designed to provide a clear and consistent approach to treating aging as a primary medical focus, and offers a roadmap for other countries to adopt similar practices in the future.</p>
<p>The DOH Scope and Standards for Healthy Longevity Medicine Facility Working Group is made up of various longevity experts, including Nicole Sirotin, CEO of IHLAD and council member of HLMS, and chaired by Andrea Maier (President, Healthy Longevity Medicine, Oon Chiew Seng Professor in Medicine, National University of Singapore), Evelyne Bischof (Professor of Medicine, longevity physician), Louis Island (Director, Healthy Longevity Medicine Society), Eric Verdin (CEO and President, Buck Institute for Research on Aging) and Thomas Rando (Director, Broad Stem Cell Research Center, UCLA).</p>
<p>“The UAE steps up as the global trailblazer leading the Healthy Longevity revolution: it is the first country to set standards for the ‘Longevity Clinic’ by defining comprehensive clinical practice guidelines,” said Dr Nicole Sirotin.</p>
<figure class="wp-block-image size-large"><img decoding="async" width="1024" height="683" src="https://longevity.technology/wp-content/uploads/2024/11/NSAM_ARDD-1024x683.jpg" alt="" class="wp-image-56077"><figcaption class="wp-element-caption">L-R: Louis Island, Nicole Sirotin, Andrea Maier, Evelyne Bischof</figcaption></figure>
<p>Sirotin emphasized the innovative collaborative effort with DOH and HLMS, which has resulted in “the world’s first evidence-based guidelines to set the standards for Healthy Longevity Medicine.”</p>
<p>“This achievement reinforces UAE’s leadership in redefining the next era of precision healthcare,” she added.</p>
<p>The growing impact of non-communicable diseases (NCDs) was central to this initiative. These diseases account for the majority of healthcare burdens globally, with aging populations increasing demand on medical systems. </p>
<p>Professor Andrea Maier, Chair of the DOH Scope and Standards Working Group, emphasized the strategic importance of prevention-focused frameworks: “Non-communicable diseases, accounting for the majority of disease burden, are on the rise as nations age. In response, healthcare systems need to reshape and focus on prevention and healthy aging, empowering citizens to manage their health proactively with support from general and specialized practices.” This structured approach offers healthcare providers a clear framework for integrating preventative strategies into medical services.</p>
<h4 class="wp-block-heading"><strong>A benchmark for healthy aging</strong></h4>
<p>The partnership’s model emphasizes several key components: advanced diagnostics, lifestyle medicine, personalized interventions and multidisciplinary care teams trained in longevity medicine. Diagnostic standards include detailed medical histories, physical examinations and biomarker testing to assess patients’ biological age and overall health status. This evidence-based approach is designed to assess aging-related risks comprehensively and initiate interventions that target aging processes directly.</p>
<p>Under the Healthy Longevity Medicine framework, diagnostic assessments are complemented by individualized care programs, including lifestyle modifications across nutrition, physical activity, cognitive health and therapeutic options. These interventions are tailored to support patients’ longevity and healthspan, ensuring that longevity care is personalized and rooted in evidence.</p>
<p>The initiative is particularly relevant as healthcare systems worldwide adapt to aging populations and growing rates of chronic diseases. Through these new guidelines, the UAE positions itself as a leader in longevity-focused healthcare, setting an example that could encourage other nations to adopt similar standards. </p>
<p>Maier added: “This strategic collaboration culminates in the development of the world’s first formalized document providing evidence-based standards for healthy longevity medicine. This pioneering framework establishes the UAE as the first nation to clearly define the scope and services required within a ‘Healthy Longevity Clinic,’ underscoring the UAE’s role in shaping global healthcare.”</p>
<h4 class="wp-block-heading"><strong>Fostering proactive health management</strong></h4>
<p>Healthy Longevity Medicine emphasizes lifestyle interventions and preventive care. To support this, the initiative integrates educational programs for clinicians, quality assurance measures and ethical protocols. Continual training programs ensure that healthcare professionals remain current with advancements in longevity science, reinforcing patient safety and aligning with global best practices. These measures aim to safeguard patient welfare, ensuring that care models are governed by stringent oversight and current scientific knowledge.</p>
<p>The project’s comprehensive care model is designed to foster a proactive health management culture where individuals are encouraged to make lifestyle adjustments that promote well-being throughout the aging process.</p>
<p>Moreover, the governance and clinical care model provide operational consistency, supported by a standardized approach in clinical procedures, safety measures and ethical care practices. This model is underpinned by detailed facility design and infrastructure standards, ensuring the physical environment of these clinics aligns with the unique requirements of Healthy Longevity Medicine.</p>
<p><strong>Setting the stage for future longevity clinics</strong></p>
<p>The broader implications of this collaboration extend beyond Abu Dhabi. This partnership serves as a model for longevity medicine that other healthcare systems may soon consider. By promoting evidence-based practices, the DOH, HLMS and IHLAD are not only addressing the needs of an aging population but also shaping the future of preventive healthcare on a global scale.</p>
<p>This pioneering framework serves as a model for longevity medicine that other healthcare systems may consider, aiming to standardize clinical practices, diagnostic procedures and quality control measures across the field. The UAE’s leadership in Healthy Longevity Medicine is further reinforced by multidisciplinary, expert-led teams, which ensure that high standards of care are maintained consistently across facilities.</p>
<p>The clinic model, supported by experienced physicians trained in longevity medicine, incorporates advanced diagnostics, targeted lifestyle interventions, and personalized care, making it well-suited to address both immediate and long-term health needs. Through these standards, Abu Dhabi hopes to influence the future of longevity clinics and healthcare delivery around the world, potentially paving the way for regulatory frameworks that prioritize preventive care and the optimization of healthspan.</p>
<p>Maier told Longevity.Technology: “It is so exciting to have government that is now embracing the idea that prevention should be the key and supporting a scope of practice for healthy longevity medicine physicians. It’s a huge milestone in the field to see a country wanting to improve and optimize health and healthspan, because they see that otherwise healthcare costs are going to rise significantly with lots of consequences.”</p>
<p>The implementation of these guidelines could lead to improved population health outcomes, a reduction in the prevalence of age-related diseases, and a more efficient allocation of healthcare resources. With a robust clinical model, encompassing advanced diagnostic standards and a clear governance structure, this initiative positions the UAE at the forefront of medical innovation. The collaborative efforts of DOH, IHLAD, and HLMS reflect a mission to set new benchmarks in longevity-focused clinical care, paving the way for a healthier future.</p>
<h6 class="wp-block-heading"><em>Main Photograph: vinnikava/Envato. Article photograph courtesy of IHLAD.</em></h6>
<p></p>
<p>The post <a href="https://longevity.technology/news/new-clinic-guidelines-to-set-global-standards-in-longevity-medicine/">New clinic guidelines to set global standards in longevity medicine</a> appeared first on <a href="https://longevity.technology/">Longevity.Technology - Latest News, Opinions, Analysis and Research</a>.</p></div>
Engineering T Cells to Fight Brain Cancer
In experiments against cultured glioblastoma cells, which do not have such a protective environment, these new cells performed just as well as other CAR T cells. These cells were also found to be target-specific: cells that do not produce EGVRvIII were not harmed by these engineered cells. In these sorts of experiments, it is relatively easy to graft human cancer cells into a mouse model and then have the CAR T cells defeat them there; however, this does not sufficiently mimic the actual tumor m
Company behind ‘world’s first AI doctor’s office’ closes down
<div><img width="525" height="350" src="https://longevity.technology/wp-content/uploads/2023/11/Forward-raises-100m-to-roll-out-AI-powered-doctors-office_HERO-1024x683.jpg" class="webfeedsFeaturedVisual wp-post-image" alt="Forward raises $100m to roll out AI-powered doctor’s office" style="display: block; margin-bottom: 5px; clear:both;max-width: 100%;" link_thumbnail="" decoding="async" sizes="(max-width: 767px) 89vw, (max-width: 1000px) 54vw, (max-width: 1071px) 543px, 580px">
<h2 class="wp-block-heading"><strong>Once a consumer health unicorn, Forward leveraged AI and advanced diagnostics to offer members personalized, preventive health plans.</strong></h2>
<p>After raising hundreds of millions in support of its mission to improve healthcare using AI and advanced digital technologies, US startup Forward has closed its doors. No reason was given for the closure, with the <a href="https://goforward.com/" target="_blank" rel="noreferrer noopener">company reporting</a> that its locations, scheduled visits and mobile application were shutting down, “effective immediately”. According to reports, all 200 Forward employees will lose their jobs, although members will still be able to access their “medical team” until mid-December.</p>
<p>Founded in 2016 by Google’s former head of special projects Adrian Aoun, Forward was initially focused on changing the primary care to a more prevention-focused and technology-enabled model. The company raised more than $500 million in total and was said to be <a href="https://www.reuters.com/article/business/exclusive-forward-health-valued-at-over-1-billion-in-latest-funding-from-softb-idUSKBN2B31EP/" target="_blank" rel="noreferrer noopener">valued at more than $1 billion</a> in 2021.</p>
<p>Last year, Forward announced another $100 million in funding and perhaps its most ambitious plan yet: the introduction of CarePods – billed as “the world’s first AI doctor’s office.” The AI-powered, self-service pods offered members personalized health plans and advanced diagnostics spanning disease detection, biometric body scans, blood testing, and more, for as little as $99 a month. </p>
<figure class="wp-block-image size-large"><img decoding="async" width="1024" height="683" src="https://longevity.technology/wp-content/uploads/2023/11/Forward-raises-100m-to-roll-out-AI-powered-doctors-office_Intext-1-1024x683.jpg" alt="Forward raises $100m to roll out AI-powered doctor’s office" class="wp-image-49042"></figure>
<p>In a <a href="https://www.linkedin.com/posts/maxmarchione_forward-digitalhealth-startups-activity-7262923176672665602-Fhcu?" target="_blank" rel="noreferrer noopener">post on LinkedIn</a>, Max Marchione, co-founder of digital longevity medicine startup <a href="https://longevity.technology/news/kapow-superpower-launches-preventative-health-and-longevity-platform/">Superpower</a>, suggested several potential reasons for Forward’s demise, but ended on a positive note.</p>
<p>“What Adrian and the team tried to do should be lauded as an attempt at the near impossible — fixing healthcare,” he said. “It’s easy for those outside the arena to critique. But really, this is a what it takes to dare to do something great. The lesson here should not be to cut down innovators. Instead, it should be to learn from the past and stand on the shoulders of giants.”</p>
<p>Dr Danish Nagda, founder and CEO of technology enabled healthcare provider Rezilient was <a target="_blank" href="https://x.com/operationdanish/status/1858503833996968349" rel="noreferrer noopener">more critical</a>, suggesting that patients rejected Forward’s mission to replace doctors and nurses with hardware and software.</p>
<p>“Their fatal error was in the fundamental assumption behind their business model: that people could be taken out of the equation in healthcare,” he said.</p>
<p>NHS cancer doctor and healthtech expert Dr Derrick Khor also <a href="https://www.linkedin.com/posts/derrick-khor_primarycare-healthcare-patients-activity-7262434136634617856-zWXc?" target="_blank" rel="noreferrer noopener">weighed in on the news</a>, suggesting that Forward’s primary focus on trying to change the primary care model in the US was likely its biggest challenge.</p>
<p>“I see the loss of Forward as a loss for the healthcare community,” he added. “Mainly because we need serious innovation in primary care. But it really begs the question, ‘Are our patients and clinicians ready for significant disruption/innovation in clinical care?’ Or are we as society more engrained into our traditional model of healthcare, however inefficient it may be? For now, it seems like the world is not quite ready yet for ‘Doctor in a Box’.”</p>
<figure class="wp-block-image size-large"><a href="https://www.surveymonkey.com/r/longevityclinics2024" target="_blank" rel="noreferrer noopener"><img decoding="async" width="1024" height="265" src="https://longevity.technology/wp-content/uploads/2024/11/longevity-clinic-survey-2024-banner-1024x265.jpg" alt="" class="wp-image-56525"></a></figure>
<h6 class="wp-block-heading"><em>Photographs: Forward Health</em></h6>
<p></p>
<p>The post <a href="https://longevity.technology/news/company-behind-worlds-first-ai-doctors-office-closes-down/">Company behind ‘world’s first AI doctor’s office’ closes down</a> appeared first on <a href="https://longevity.technology/">Longevity.Technology - Latest News, Opinions, Analysis and Research</a>.</p></div>
Ten Levels of Longevity: #2 consumer diagnostics
Consumer diagnostics involve the analysis of various data sources – such as blood samples, genetic information and lifestyle habits – to provide personalized health insights. By leveraging AI and machine learning, these diagnostics can interpret complex datasets, offering individuals tailored recommendations to improve their health and potentially extend their lifespan. A significant trend in this domain is the development of multiomics platforms that integrate genomics, proteomics, metabolomics
How Depression Alters Stress, Health, and Lifespan
<div><a href="https://neurosciencenews.com/depression-stress-longevity-28066/" title="How Depression Alters Stress, Health, and Lifespan" rel="nofollow"><img width="1155" height="770" src="https://neurosciencenews.com/files/2024/11/depression-stress-lifespan-neuroscience-1155x770.jpg" class="webfeedsFeaturedVisual wp-post-image" alt="This shows a head." style="float: left; margin-right: 5px;" link_thumbnail="1" decoding="async" fetchpriority="high" srcset="https://neurosciencenews.com/files/2024/11/depression-stress-lifespan-neuroscience-1155x770.jpg 1155w, https://neurosciencenews.com/files/2024/11/depression-stress-lifespan-neuroscience-300x200.jpg 300w, https://neurosciencenews.com/files/2024/11/depression-stress-lifespan-neuroscience-770x513.jpg 770w, https://neurosciencenews.com/files/2024/11/depression-stress-lifespan-neuroscience-370x247.jpg 370w, https://neurosciencenews.com/files/2024/11/depression-stress-lifespan-neuroscience-293x195.jpg 293w, https://neurosciencenews.com/files/2024/11/depression-stress-lifespan-neuroscience-150x100.jpg 150w, https://neurosciencenews.com/files/2024/11/depression-stress-lifespan-neuroscience.jpg 1200w" sizes="(max-width: 1155px) 100vw, 1155px"></a>Depression disrupts the body's stress systems, causing physical health risks like heart disease, diabetes, and stroke, and reducing life expectancy by 7-10 years. The condition triggers brain structure changes, such as a 40% reduction in subgenual prefrontal cortex volume, and disrupts hormone systems involving CRH, norepinephrine, and cortisol.</div>
‘The NAD+ system is under daily attack – it needs boosting’
ChromaDex’s Dr Charles Brenner talks NAD+ and explains how Niagen enhances resilience against metabolic stress.
Yesterday, Longevity.Technology announced a new venture – the launch of its consumer products division, dedicated to science-backed longevity solutions. Our inaugural product, the Longevity.Technology LONGEVITY supplement, showcases a unique blend of evidence-based ingredients aimed at enhancing healthspan and cellular vitality.
A major highlight of this launch is the partnersh
Singapore Founders Longevity Forum reveals first wave of speakers
<div><img width="525" height="350" src="https://longevity.technology/wp-content/uploads/2024/11/Singapore-Founders-Longevity-Forum-reveals-first-wave-of-speakers-1024x683.jpg" class="webfeedsFeaturedVisual wp-post-image" alt="" style="display: block; margin-bottom: 5px; clear:both;max-width: 100%;" link_thumbnail="" decoding="async" sizes="(max-width: 767px) 89vw, (max-width: 1000px) 54vw, (max-width: 1071px) 543px, 580px">
<h2 class="wp-block-heading"><strong>A global gathering for thought leaders in longevity science and technology heads to Singapore in 2025 for its next edition.</strong></h2>
<p>The <a href="https://eventregistration.ff.co/founderslongevityforumsingaporestandardprice/aboutyou" target="_blank" rel="noreferrer noopener sponsored nofollow">Founders Longevity Forum</a>, a pivotal event in the global longevity sector, <a href="https://longevity.technology/news/founders-longevity-forum-heads-to-singapore/" target="_blank" rel="noreferrer noopener">is set to return in 2025</a>, with Singapore as its host. Known for convening influential voices from science, technology, investment and healthcare, the forum provides an unparalleled platform for discussing innovations and advancements aimed at extending healthspan and tackling the challenges of aging. As the longevity field continues to grow, the Singapore edition promises to bring together diverse perspectives from around the world, fostering collaboration across disciplines and industries.</p>
<p>Organized and hosted by <a href="https://ff.co/" target="_blank" rel="noreferrer noopener">Founders Forum</a>, the <a href="https://nus.edu.sg/" target="_blank" rel="noreferrer noopener">National University of Singapore</a> and <a href="https://longevity.technology/" target="_blank" rel="noreferrer noopener">Longevity.Technology</a>, the <a href="https://eventregistration.ff.co/founderslongevityforumsingaporestandardprice/aboutyou" target="_blank" rel="noreferrer noopener sponsored nofollow">2025 event</a> will feature a dynamic roster of speakers, including leaders from epigenetics, AI, cryomedicine and preventative healthcare. While the agenda is yet to be released, the <a href="https://longevity.technology/news/ticketing-now-live-for-founders-longevity-forum-singapore/" target="_blank" rel="noreferrer noopener">Forum has revealed</a> the event will be structured to allow attendees to engage with content relevant to their specific interests through three distinct tracks: Precision Geromedicine, ‘Longevity Now’ and Longevity Investment. The organizers have now announced the first wave of confirmed participants, each bringing a unique expertise to the table.</p>
<figure class="wp-block-image size-large"><img decoding="async" width="1024" height="683" src="https://longevity.technology/wp-content/uploads/2024/11/FLF-Image-1024x683.jpg" alt="" class="wp-image-56501"></figure>
<h4 class="wp-block-heading">Elvin Siew – Co-Founder & CEO at Emagene Life and Avio Health</h4>
<p>Siew drives advancements in healthcare using artificial intelligence and machine learning to revolutionize diagnostics and treatment options.</p>
<h4 class="wp-block-heading">Hannah Went – Director of Operations at TruDiagnostic</h4>
<p>Went oversees operations at TruDiagnostic, a leading provider of epigenetic testing that offers personalized health insights based on DNA methylation analysis.</p>
<figure class="wp-block-image size-large"><img decoding="async" width="1024" height="683" src="https://longevity.technology/wp-content/uploads/2024/11/Hannah-Went-1024x683.jpg" alt="" class="wp-image-56487"><figcaption class="wp-element-caption">Hannah Went – Director of Operations at TruDiagnostic</figcaption></figure>
<h4 class="wp-block-heading">Tina Woods – Founder & CEO at Collider Health</h4>
<p>Woods unites stakeholders from science, technology and policy to drive initiatives aimed at improving public health and fostering innovation in the longevity space.</p>
<h4 class="wp-block-heading">Dr David Luu – CEO at Hearty</h4>
<p>Luu combines his medical expertise with a passion for humanitarianism, democratizing cardiac care in underserved regions through mobile clinics and surgical interventions.</p>
<figure class="wp-block-image size-large"><img decoding="async" width="1024" height="683" src="https://longevity.technology/wp-content/uploads/2024/11/David-Luu-1024x683.jpg" alt="" class="wp-image-56488"><figcaption class="wp-element-caption">Dr David Luu – CEO at Hearty</figcaption></figure>
<h4 class="wp-block-heading">Dr Jan Gruber – Associate Professor at National University of Singapore and Yale-NUS College</h4>
<p>Gruber’s research spans aging, mitochondria, pharmacological interventions and biological aging clocks.</p>
<h4 class="wp-block-heading">Bhuvan Srinivasan – Chief Business Officer at Ultrahuman</h4>
<p>With a background in private equity and research in continuous glucose monitoring, Srinivasan contributes to Ultrahuman’s mission of optimizing metabolic health while supporting startups as an angel investor.</p>
<figure class="wp-block-image size-large"><img decoding="async" width="1024" height="683" src="https://longevity.technology/wp-content/uploads/2024/11/Bhuvan-Srinivasan-1024x683.jpg" alt="" class="wp-image-56493"><figcaption class="wp-element-caption">Bhuvan Srinivasan – Chief Business Officer at Ultrahuman</figcaption></figure>
<h4 class="wp-block-heading">Dr Emil Kendziorra – CEO at Tomorrow Bio</h4>
<p>Kendziorra focuses on advancing biostasis and cryomedicine, leveraging his experience as a serial entrepreneur in technology and healthcare.</p>
<h4 class="wp-block-heading">Professor Luigi Fontana – Professor at the University of Sydney</h4>
<p>Fontana advocates for preventative healthcare approaches to promote long and healthy lives while addressing environmental sustainability.</p>
<h4 class="wp-block-heading">Petr Sramek – Managing Partner at Longevity.tech Fund</h4>
<p>Sramek supports the growth of AI and longevity startups, providing mentorship and strategic guidance to emerging companies in the field.</p>
<figure class="wp-block-image size-large"><img decoding="async" width="1024" height="683" src="https://longevity.technology/wp-content/uploads/2024/11/Petr-Sramek-1024x683.jpg" alt="" class="wp-image-56491"><figcaption class="wp-element-caption">Petr Sramek – Managing Partner at Longevity.tech Fund</figcaption></figure>
<h4 class="wp-block-heading">Dr Anna Erat – Medical Director at Longevity Center Zurich</h4>
<p>Erat blends clinical practice with research, advising on health strategies for a wide range of clients, from multi-morbid patients to elite athletes.</p>
<h4 class="wp-block-heading">Yuta Lee – Founder & CEO at Accelerated Biosciences</h4>
<p>Lee brings decades of expertise in commercializing human trophoblast stem cells, advancing ethical stem cell research.</p>
<figure class="wp-block-image size-large"><img decoding="async" width="1024" height="683" src="https://longevity.technology/wp-content/uploads/2024/11/Yuta-Lee-headshot-1024x683.jpg" alt="" class="wp-image-56489"><figcaption class="wp-element-caption">Yuta Lee – Founder & CEO at Accelerated Biosciences</figcaption></figure>
<h4 class="wp-block-heading">Dr Siobhan Mitchell – Chief Science and Technology Officer at MitoQ</h4>
<p>Mitchell’s work centers on clinical trial management, focusing on studies that address behavior change, mental health, cognition and metabolism.</p>
<h4 class="wp-block-heading">Luc Aguilar – International R&D Director at L’Oréal</h4>
<p>Aguilar leads research in skin and hair microbiome science, translating findings into products addressing pollution, sun damage and skin disorders.</p>
<h4 class="wp-block-heading">Dr David Dodick – Chief Science Officer and Co-Chair at Atria</h4>
<p>Dodick brings his extensive experience in neurology, having founded multiple programs and held academic positions across prestigious institutions.</p>
<figure class="wp-block-image size-large"><img decoding="async" width="1024" height="683" src="https://longevity.technology/wp-content/uploads/2024/11/David-Dodick-1024x683.jpg" alt="" class="wp-image-56490"><figcaption class="wp-element-caption">Dr David Dodick – Chief Science Officer and Co-Chair at Atria</figcaption></figure>
<h4 class="wp-block-heading">Dr Mattias Bernow – CEO at Cellcolabs</h4>
<p>Bernow operates at the intersection of healthcare and business, focusing on digi-physical healthcare solutions that integrate technology and patient care.</p>
<h4 class="wp-block-heading">Max Van Zanten – Investment & Business Development at Wellness Holding</h4>
<p>Van Zanten specializes in wellness technologies, driving global marketing strategies for TechnoGym and fostering innovation in fitness.</p>
<h4 class="wp-block-heading">Dr Frank Pun – Head at Insilico Medicine Hong Kong</h4>
<p>Pun leads a team using AI-driven platforms for biological target discovery, advancing drug development through innovative approaches.</p>
<figure class="wp-block-image size-large"><img decoding="async" width="1024" height="683" src="https://longevity.technology/wp-content/uploads/2024/11/Frank-Pun-1024x683.jpg" alt="" class="wp-image-56492"><figcaption class="wp-element-caption">Dr Frank Pun – Head at Insilico Medicine Hong Kong</figcaption></figure>
<h4 class="wp-block-heading">Professor Andrea Maier – NUS Oon Chiew Seng Professor in Medicine and Founder at Chi Longevity</h4>
<p>Maier’s expertise in gerontology and geriatrics focuses on preventing age-related diseases and extending healthspan.</p>
<h4 class="wp-block-heading">Phil Newman – CEO and Founder at Longevity.Technology</h4>
<p>Newman, a driving force in longevity innovation, connects investors and startups through his work with Longevity.Technology and First Longevity.</p>
<p>The <a href="https://eventregistration.ff.co/founderslongevityforumsingaporestandardprice/aboutyou" target="_blank" rel="noreferrer noopener sponsored nofollow">Founders Longevity Forum</a> promises to be a vital event for fostering meaningful dialogue and collaboration across the longevity ecosystem. Further updates, including the agenda and additional speakers, are expected soon.</p>
<figure class="wp-block-image size-large is-resized"><img decoding="async" width="1024" height="683" src="https://longevity.technology/wp-content/uploads/2024/11/Phil-Newman-White-Background-T-shirt-Jacket-1024x683.jpg" alt="" class="wp-image-56494" style="width:674px;height:auto"><figcaption class="wp-element-caption">Phil Newman – CEO and Founder at Longevity.Technology</figcaption></figure>
<h4 class="wp-block-heading"><strong><a href="https://eventregistration.ff.co/founderslongevityforumsingaporestandardprice/aboutyou" target="_blank" rel="noreferrer noopener sponsored nofollow">Reserve your spot today and be at the forefront of longevity innovation – join the conversation that’s shaping the future of healthcare and investment</a></strong>.</h4>
<p></p>
<p>The post <a href="https://longevity.technology/news/singapore-founders-longevity-forum-reveals-first-wave-of-speakers/">Singapore Founders Longevity Forum reveals first wave of speakers</a> appeared first on <a href="https://longevity.technology/">Longevity.Technology - Latest News, Opinions, Analysis and Research</a>.</p></div>
65% of longevity clinicians think Bryan Johnson adds value
<div><img width="525" height="350" src="https://longevity.technology/wp-content/uploads/2024/11/LT-survey-1024x683.jpg" class="webfeedsFeaturedVisual wp-post-image" alt="" style="display: block; margin-bottom: 5px; clear:both;max-width: 100%;" link_thumbnail="" decoding="async" sizes="(max-width: 767px) 89vw, (max-width: 1000px) 54vw, (max-width: 1071px) 543px, 580px">
<h2 class="wp-block-heading"><strong>Our 2024 Longevity Clinics Survey is open with respondents from all over the world: Have you participated yet?</strong></h2>
<p>Beyond the beneficial data that our survey shares on diagnostic approaches: imaging, cardio, cognitive screening, etc., and interventions offered: peptides, stem cell therapy, PRP, IV therapies, etc., our current survey is delivering some really fascinating results:</p>
<ul class="wp-block-list">
<li>67% pursue CMEs (Continuing Medical Education) in healthy longevity medicine.</li>
<li>21% won’t take on patients with serious existing health conditions.</li>
<li>59% think that longevity practice software tools are OK but need more work.</li>
<li>73% help clients identify or manage their biological vs chronological age, which means 27% do not.</li>
</ul>
<p>But if you want to be on the inside track of questions like client demographics, commercial growth, profitability, client acquisition, do clinics have sufficient numbers of clients, etc., then, if you’re a longevity clinician/clinic, we need 15 minutes of your time to help complete the survey.</p>
<p>The findings from this survey will be presented at the upcoming <a href="https://longevity.technology/news/setting-the-stage-for-the-future-of-longevity-clinics/" target="_blank" rel="noreferrer noopener">Roundtable of Longevity Clinics</a>, and as a ‘thank you’ for completing it, respondents will get:</p>
<ul class="wp-block-list">
<li>10% off the normal price of the ticket for the <a href="https://longevity-roundtable.com/" target="_blank" rel="noreferrer noopener nofollow">Roundtable of Longevity clinics</a> taking place at the Buck Institute between 6-7th December 2024.</li>
<li>The chance to see the results ahead of our comprehensive report on the data gathered.</li>
<li>Automatic entry into the prize draw for a free ticket to our <a href="https://longevity.technology/news/ticketing-now-live-for-founders-longevity-forum-singapore/" target="_blank" rel="noreferrer noopener">longevity/clinical conference in Singapore on 27-28 February 2025</a>.*</li>
</ul>
<p>Here’s the <a href="https://www.surveymonkey.com/r/longevityclinics2024" target="_blank" rel="noreferrer noopener nofollow">link</a> and QR!</p>
<figure class="wp-block-image size-large"><a href="https://www.surveymonkey.com/r/longevityclinics2024" target="_blank" rel="noreferrer noopener"><img decoding="async" width="1024" height="640" src="https://longevity.technology/wp-content/uploads/2024/11/QR-2-1024x640.jpg" alt="" class="wp-image-56496"></a></figure>
<p>Oh, and the <a href="https://longevity.technology/tag/bryan-johnson/" target="_blank" rel="noreferrer noopener">Bryan Johnson</a> question was: Do you think Bryan Johnson contributes to (i.e. creates awareness) or hinders (i.e. subverts proper medicine) the progress of longevity medicine?</p>
<figure class="wp-block-image size-large"><img decoding="async" width="1024" height="521" src="https://longevity.technology/wp-content/uploads/2024/11/BJ-Grid-1024x521.jpg" alt="" class="wp-image-56498"></figure>
<p>Don’t agree? Then do join the survey and contribute your opinion.</p>
<p>We have had some excellent comments from leading professionals in the field, and we want to hear what <strong>you</strong> have to say – we’re live for another two weeks,<a href="https://www.surveymonkey.com/r/longevityclinics2024" target="_blank" rel="noreferrer noopener nofollow"> so please join the conversation!</a></p>
<p></p>
<hr class="wp-block-separator has-alpha-channel-opacity is-style-wide">
<h4 class="wp-block-heading">* Prize Draw Terms and Conditions</h4>
<p><strong>1. Eligibility</strong><br>This prize draw is open to qualified clinicians aged 18 years or over, excluding employees of First Longevity Ltd or their immediate families, agents, or any third party directly associated with the administration of the prize draw. By entering the prize draw, participants agree to be bound by these terms and conditions.</p>
<p><strong>2. How to enter<br></strong>Entry to the prize draw is free. Participants will be automatically entered when they complete the full survey provided by First Longevity Ltd. Only one entry per person is permitted. Multiple entries from the same person will be disqualified. The closing date for entries is 01 December 2024. Entries received after this time will not be accepted.</p>
<p><strong>3. Prize<br></strong>The prize is one ticket to the Longevity/Clinical Conference in Singapore on 27-28 February 2025. Travel, accommodation, and any other expenses associated with attending the conference are not included in the prize. The prize is non-exchangeable, non-transferable, and no cash alternative is offered. First Longevity Ltd reserves the right to replace the prize with an alternative of equal or higher value if circumstances beyond its control make it necessary to do so.</p>
<p><strong>4. Winner selection and notification<br></strong>The winner will be chosen by random draw supervised by an independent person within 14 days of the closing date. The winner will be notified by email (using details provided at entry) within 7 days of the draw. If the winner does not respond to the email within 14 days of notification, they will forfeit their prize, and First Longevity Ltd will select another winner at random. The decision of First Longevity Ltd regarding any aspect of the prize draw is final and binding and no correspondence will be entered into.</p>
<p><strong>5. Data protection and publicity<br></strong>First Longevity Ltd will only process personal information as set out in its Privacy Policy, which can be found at <a href="http://www.longevity.technology/" target="_blank" rel="noreferrer noopener">www.longevity.technology</a>. The winner’s name and organization may be announced on First Longevity Ltd’s website and social media channels. If you object to any or all of your surname, organization, and winning entry being published or made available, please contact First Longevity Ltd.</p>
<p><strong>6. General</strong><br>First Longevity Ltd reserves the right to cancel, amend, or suspend the prize draw if necessary due to circumstances outside its control. The prize draw will be governed by English law and entrants to the prize draw submit to the jurisdiction of the English courts.</p>
<p>The post <a href="https://longevity.technology/news/65-of-longevity-clinicians-think-bryan-johnson-adds-value/">65% of longevity clinicians think Bryan Johnson adds value</a> appeared first on <a href="https://longevity.technology/">Longevity.Technology - Latest News, Opinions, Analysis and Research</a>.</p></div>
Study of Direct Reprogramming Challenges Consensus
In the world of cellular reprogramming, the two most well-known realms are pluripotent reprogramming, in which somatic cells are thrown back all the way into pluripotency, and partial reprogramming, in which these cells are rejuvenated without making them lose their cellular identity. Yamanaka Factors - Opportunities for RejuvenationDrs. Takahashi and Yamanaka showed that they could use Oct4, Sox2, Klf4, and c-Myc (OSKM) to reprogram cells back to pluripotent, embryonic stem cells. While this di
Metsera lands £215m to accelerate obesity and metabolic disease pipeline
Founded in 2022 by Population Health Partners and ARCH Venture Partners, Metsera only officially launched earlier this year and is developing next-generation medicines using nutrient-stimulated hormone (NuSH) analog peptides, with a portfolio encompassing both oral and injectable incretin and non-incretin therapies. NuSH peptides include GLP-1 agonists, like Ozempic/Wegovy, which are increasingly garnering attention for their potential to influence longevity. It appears GLP-1s not only promote w
Preventing Alzheimer’s Proteins From Accumulating
<div><p style="text-align: justify;"><a href="https://onlinelibrary.wiley.com/doi/10.1111/acel.14404">Boosting a key autophagy-related protein discourages a core component of Alzheimer’s from taking hold</a>, according to a study published in <i>Aging Cell</i>.</p>
<h2 style="text-align: justify;"><b>Taking out the trash</b></h2>
<p style="text-align: justify;">Autophagy is the maintenance process of the cell, in which autophagosomes engulf unwanted organelles and other material and fuse together with lysosomes to be digested. As these unwanted components include such things as misfolded proteins, this is far from the first study to link autophagic deficiencies to Alzheimer’s [1, 2].</p>
<p style="text-align: justify;">Along with the well-known amyloid beta, misfolded and modified tau is the key biomarker of Alzheimer’s disease. Tau is a necessary protein for brain function, as it provides key functions for structure and signaling [3]; however, it can also be modified in a very large number of ways, many of which lead to the death of neurons and thus cognitive decline [4]. The most well-known, and possibly most dangerous, is phosphorylation, and phosphorylated tau has been known to be core to Alzheimer’s for decades [5]. Even worse, an excess of misfolded tau can cause failures in autophagy, leading to a rapid increase in the related problems [6].</p>
<p style="text-align: justify;">To fight back against this process and restore autophagy to distressed neurons, this research focuses on tectonin beta-propeller repeat-containing protein 1 (TECPR1), which encourages autophagosomes and lysosomes to fuse [7], accelerates the consumption of protein aggregates, including in stem cells [8], and repairs damaged lysosomes [9]. However, TECPR1 had never been previously investigated in the context of Alzheimer’s.</p>
<h2 style="text-align: justify;"><b>Tau tangles lead to impaired clearance</b></h2>
<p style="text-align: justify;">This study began by causing a harmful, mutated form of tau, P301S-tau, to form in HEK293 human kidney cells. They found two harmful effects: first, that P301S-tau was discouraging autophagosomes from forming in the first place and then that this form of tau was preventing autophagosomes and lysosomes from combining.</p>
<p style="text-align: justify;">This finding was replicated in mice. Transgenic mice that expressed P301S-tau actually had more autophagosomes than wild-type mice; they were just unable to complete their jobs, being left free-floating within the cell. As the researchers expected, there was far less TECPR1 in the cells of the transgenic mice, including in hippocampal neurons, which are responsible for learning and memory; this held true whether the mice were born transgenic or transfected with a retrovirus at a young age. The levels of other autophagy-related proteins were also heavily dysregulated.</p>
<p style="text-align: justify;">Transfecting HEK293 cells with TECPR1 appeared to do the opposite of P301S-tau. More autophagosomes were created in the TECPR1-transfected cells, and autosomal and lysosomal fusion was increased as well.</p>
<h2 style="text-align: justify;"><b>TECPR1 fights tau tangles in mice</b></h2>
<p style="text-align: justify;">With these positive results in hand, the researchers then turned to their mouse population. 8-month-old wild-type and P301S mice were transfected with a retrovirus that causes the overexpression of TECPR1, then studied a month later. In wild-type mice, this did nothing in terms of brain capability; there were no changes in learning ability nor behavior.</p>
<p style="text-align: justify;">However, in the P301S group, there were a few marked changes. In the Morris water maze test, P301S mice were much slower to explore, and their memory was much worse. Transfection with TECPR1 brought these metrics much closer to those of wild-type mice. The transfection also caused benefits in object recognition; TECPR1-treated P301S mice were much better at distinguishing between new and old objects than their untreated, tau-tangled counterparts, and they had a greater ability to retain fear memories as well.</p>
<p style="text-align: justify;"><img fetchpriority="high" decoding="async" class="aligncenter wp-image-133343 size-full" src="https://www.lifespan.io/wp-content/uploads/2024/11/TECPR1-Mouse-Results.png" alt="TECPR1 Mouse Results" width="916" height="1178" srcset="https://www.lifespan.io/wp-content/uploads/2024/11/TECPR1-Mouse-Results.png 916w, https://www.lifespan.io/wp-content/uploads/2024/11/TECPR1-Mouse-Results-311x400.png 311w, https://www.lifespan.io/wp-content/uploads/2024/11/TECPR1-Mouse-Results-308x396.png 308w, https://www.lifespan.io/wp-content/uploads/2024/11/TECPR1-Mouse-Results-199x256.png 199w, https://www.lifespan.io/wp-content/uploads/2024/11/TECPR1-Mouse-Results-233x300.png 233w, https://www.lifespan.io/wp-content/uploads/2024/11/TECPR1-Mouse-Results-796x1024.png 796w, https://www.lifespan.io/wp-content/uploads/2024/11/TECPR1-Mouse-Results-150x193.png 150w, https://www.lifespan.io/wp-content/uploads/2024/11/TECPR1-Mouse-Results-480x617.png 480w, https://www.lifespan.io/wp-content/uploads/2024/11/TECPR1-Mouse-Results-600x772.png 600w, https://www.lifespan.io/wp-content/uploads/2024/11/TECPR1-Mouse-Results-360x463.png 360w, https://www.lifespan.io/wp-content/uploads/2024/11/TECPR1-Mouse-Results-262x337.png 262w, https://www.lifespan.io/wp-content/uploads/2024/11/TECPR1-Mouse-Results-555x714.png 555w, https://www.lifespan.io/wp-content/uploads/2024/11/TECPR1-Mouse-Results-300x386.png 300w" sizes="(max-width: 916px) 100vw, 916px"></p>
<p style="text-align: justify;">These findings were confirmed when the mice’s brains were analyzed. While TECPR1 did nothing beneficial for wild-type mice, using it to combat the mutant tau caused the neurons to stay alive and to make more connections with other neurons. Fundamental proteins that were reduced with P301S were restored with TECPR1. Overall, the researchers concluded that TECPR1 restores neuroplasticity to tau-impaired mice.</p>
<p style="text-align: justify;">Further work found that the mechanism of action was indeed as the researchers had believed: both total tau and phosphorylated tau were reduced in the hippocampi of the P301S mice. An examination of gene expression found that TECPR1 did not affect the production of tau, only its consumption, and further work found that administering other autophagy-inhibiting compounds will prevent TECPR1 from having any positive effect.</p>
<p style="text-align: justify;">With these results, the researchers believe that TECPR1 is a good target for treating Alzheimer’s disease. However, there are no known methods of getting more TECPR1 into the neurons of living people. To begin a clinical trial, either a gene therapy, ideally <a href="https://www.lifespan.io/news/towards-fine-tuned-control-of-gene-expression">one that only targets the affected neurons</a>, must be developed or a small molecule or nanoparticle must be found to efficiently administer TECPR1 into the affected cells or to cause them to upregulate it themselves.</p>
<div class="textwidget"><div class="sep-2"></div>
<div class="life-highlight-box lhbox-has-zoom-yes l-hbox-size-large l-hbox-edges-square" style="background-color: #cef0f5;"><div class="l-hbox-lower"><div class="l-hbox-lower-desc" style="color:#000;">We would like to ask you a small favor. <strong>We are a non-profit foundation</strong>, and unlike some other organizations, we have no shareholders and no products to sell you. <strong>All our news and educational content is free</strong> for everyone to read, but it does mean that we rely on the help of people like you. Every contribution, no matter if it’s big or small, <strong>supports independent journalism</strong> and sustains our future. </div><style>.rb--fe515b7ba98901 a {background-color:#1e4fba;}.rb--fe515b7ba98901 a:hover {background-color:#79bcf0;}</style><div class="l-hbox-lower-cta rb--fe515b7ba98901"><a href="https://www.lifespan.io/how-you-can-help/" target="_self" rel="noopener">Yes I will donate❤️</a></div></div></div>
</div>
<h2 style="text-align: justify;"><b>Literature</b></h2>
<p style="text-align: justify;">[1] Zhang, Z., Yang, X., Song, Y. Q., & Tu, J. (2021). Autophagy in Alzheimer’s disease pathogenesis: Therapeutic potential and future perspectives. <i>Ageing research reviews</i>, <i>72</i>, 101464.</p>
<p style="text-align: justify;">[2] Zhang, W., Xu, C., Sun, J., Shen, H. M., Wang, J., & Yang, C. (2022). Impairment of the autophagy–lysosomal pathway in Alzheimer’s diseases: pathogenic mechanisms and therapeutic potential. <i>Acta Pharmaceutica Sinica B</i>, <i>12</i>(3), 1019-1040.</p>
<p style="text-align: justify;">[3] Wang, J. Z., & Liu, F. (2008). Microtubule-associated protein tau in development, degeneration and protection of neurons. <i>Progress in neurobiology</i>, <i>85</i>(2), 148-175.</p>
<p style="text-align: justify;">[4] Li, C., & Götz, J. (2017). Tau-based therapies in neurodegeneration: opportunities and challenges. <i>Nature Reviews Drug Discovery</i>, <i>16</i>(12), 863-883.</p>
<p style="text-align: justify;">[5] Braak, H., & Braak, E. (1991). Neuropathological stageing of Alzheimer-related changes. <i>Acta neuropathologica</i>, <i>82</i>(4), 239-259.</p>
<p style="text-align: justify;">[6] Feng, Q., Luo, Y., Zhang, X. N., Yang, X. F., Hong, X. Y., Sun, D. S., … & Wang, J. Z. (2020). MAPT/Tau accumulation represses autophagy flux by disrupting IST1-regulated ESCRT-III complex formation: a vicious cycle in Alzheimer neurodegeneration. <i>Autophagy</i>, <i>16</i>(4), 641-658.</p>
<p style="text-align: justify;">[7] Kim, J. H., Hong, S. B., Lee, J. K., Han, S., Roh, K. H., Lee, K. E., … & Song, H. K. (2015). Insights into autophagosome maturation revealed by the structures of ATG5 with its interacting partners. <i>Autophagy</i>, <i>11</i>(1), 75-87.</p>
<p style="text-align: justify;">[8] Wetzel, L., Blanchard, S., Rama, S., Beier, V., Kaufmann, A., & Wollert, T. (2020). TECPR1 promotes aggrephagy by direct recruitment of LC3C autophagosomes to lysosomes. <i>Nature communications</i>, <i>11</i>(1), 2993.</p>
<p style="text-align: justify;">[9] Corkery, D. P., Castro‐Gonzalez, S., Knyazeva, A., Herzog, L. K., & Wu, Y. W. (2023). An ATG12‐ATG5‐TECPR1 E3‐like complex regulates unconventional LC3 lipidation at damaged lysosomes. <i>EMBO reports</i>, <i>24</i>(9), e56841.</p>
<div id="playht-shortcode" data-shortcode='
<div
id="playht-iframe-wrapper"
style="display:flex; max-height:"90px"; justify-content:center">
<iframe
allowfullscreen=""
frameborder="0"
scrolling="no"
class="playht-iframe-player"
data-appId="E9FaMfn-qe"
article-url="https://www.lifespan.io/?p=133342"
data-voice="en-US-BrandonNeural"
src="https://play.ht/embed/?article_url=https://www.lifespan.io/?p=133342&voice=en-US-BrandonNeural&config={"width":""100%"","height":""90px"","alignment":"center","title":"Audio","message":"Hello","download_text_button":"Download"}"
width=""100%""
height=""90px""
style="max-height:"90px"">
</iframe>
</div>'></div></div>
Longevity.Technology® debuts LONGEVITY Supplement: A science-driven approach to healthspan
<div><img width="525" height="350" src="https://longevity.technology/lifestyle/wp-content/uploads/2024/11/LT-Supplements-3.jpg" class="webfeedsFeaturedVisual wp-post-image" alt="" style="display: block; margin-bottom: 5px; clear:both;max-width: 100%;" link_thumbnail="" decoding="async" sizes="100vw">
<p>Longevity.Technology® is excited to announce the launch of its first supplement, <a href="http://www.longevity.technology/store/?utm_source=lt_lifestyle&utm_medium=launch_article&utm_campaign=longevity_launch_article" target="_blank" rel="noreferrer noopener">LONGEVITY</a>, as part of its new consumer products division. </p>
<p>In partnership with leading researchers and ingredient suppliers, <a href="https://longevity.technology/store/product/longevity-supplement/?utm_source=lt_lifestyle&utm_medium=launch_article&utm_campaign=longevity_launch_article" target="_blank" rel="noreferrer noopener">Longevity.Technology® LONGEVITY</a> represents a groundbreaking supplement designed to enhance healthspan through a blend of scientifically-backed ingredients targeting cellular health.</p>
<h2 class="wp-block-heading" id="h-collaboration-with-chromadex-and-the-power-of-niagen"><strong>Collaboration with ChromaDex and the power of Niagen®</strong></h2>
<p>Longevity.Technology has collaborated with ChromaDex, a pioneer in NAD+ research, to incorporate Niagen® (nicotinamide riboside, NR) as one of LONGEVITY’s core ingredients. </p>
<p>Supported by extensive human clinical studies, Niagen® has been shown to elevate NAD+ levels, a coenzyme essential for mitochondrial health and energy production, helping cells repair DNA and combat the impacts of aging [1].</p>
<p>“Out of all the NAD+ boosters, NR, NMN, and NAD+, Niagen NR is the most efficient, safe, and legal NAD+ precursor available,” said Charles Brenner, PhD, Alfred E Mann Family Foundation Chair in Diabetes and Cancer Metabolism in the Department of Diabetes & Cancer Metabolism and ChromaDex’s Chief Scientific Adviser.</p>
<h2 class="wp-block-heading" id="h-evidence-based-ingredients-for-optimal-aging"><strong>Evidence-based ingredients for optimal aging</strong></h2>
<p>Guided by Longevity.Technology’s core mission to enhance healthspan with science-backed products, LONGEVITY delivers a <a href="https://longevity.technology/store/science/?utm_source=lt_lifestyle&utm_medium=launch_article&utm_campaign=longevity_launch_article" target="_blank" rel="noreferrer noopener">unique combination of ingredients</a> proven to help you thrive at every stage of life.</p>
<p>The supplement’s formulation centers around five powerful ingredients, each targeting a specific aspect of cellular health and longevity:</p>
<ul class="wp-block-list">
<li><strong>Niagen® (Nicotinamide Riboside)</strong> – The driving force behind cellular energy, Niagen raises NAD+ levels, a crucial coenzyme that declines with age. By boosting NAD+, Niagen supports DNA repair, mitochondrial function, and metabolic processes, helping keep your cells functioning optimally [2, 3]. With over 30 peer-reviewed human clinical studies, Niagen is among the most researched and trusted NAD+ boosters, making it a core component of Longevity.Technology® LONGEVITY.<br></li>
<li><strong>Fisetin</strong> – Known for its senolytic properties, Fisetin clears out dysfunctional cells [4] that accumulate with age, preventing cellular “clutter” that accelerates aging. By removing these senescent cells, Fisetin enables healthier cells to thrive, protecting against stress-related cellular damage and supporting an efficient [5], youthful cellular environment.<br></li>
<li><strong>Resveratrol </strong>– A potent antioxidant, Resveratrol helps reduce inflammation and supports cognitive function, and mitochondrial activity [6], [7]. Studies have shown Resveratrol’s ability to promote healthy aging by enhancing mitochondrial biogenesis [8] and supporting a balanced inflammatory response, both crucial to maintaining vitality as you age.<br></li>
<li><strong>ErgoActive® (L-Ergothioneine)</strong> – Often called the “longevity vitamin” [9] L-Ergothioneine acts as a powerful antioxidant that protects telomeres (the protective caps at the end of chromosomes) from shortening [10], a key indicator of cellular aging. It helps guard against age-related diseases by shielding cells from oxidative stress and preserving mitochondrial and cellular health. With its unique role in aging, ErgoActive® is essential for cellular resilience and long-term wellness.<br></li>
<li><strong>Spermidine ( from Wheat Germ Extract)</strong> – Stimulating autophagy [11] – the body’s natural process of clearing out damaged cell components – Spermidine helps keep cells youthful and healthy. It plays a critical role in cellular renewal, promoting an efficient cellular recycling system that helps delay the visible effects of aging [12].</li>
</ul>
<h2 class="wp-block-heading" id="h-unmatched-quality-and-proven-science"><strong>Unmatched quality and proven science</strong></h2>
<p><a href="https://longevity.technology/store/product/longevity-supplement/?utm_source=lt_lifestyle&utm_medium=launch_article&utm_campaign=longevity_launch_article" target="_blank" rel="noreferrer noopener">Longevity.Technology® LONGEVITY</a> is crafted with the highest standards to deliver tangible results you can trust. Manufactured in the USA under stringent cGMP standards, each batch of this supplement undergoes comprehensive quality testing to ensure it meets and exceeds industry standards. </p>
<p>This meticulous process reflects Longevity.Technology’s unwavering commitment to providing safe, effective products that readers and consumers can depend on.</p>
<p>As a respected leader in the longevity field, Longevity.Technology prioritizes transparency and integrity. Unlike many supplements that lean on animal studies or early-stage data, this supplement is built on a foundation of ingredients backed by human trials, ensuring <a href="https://longevity.technology/store/studies/?utm_source=lt_lifestyle&utm_medium=launch_article&utm_campaign=longevity_launch_article" target="_blank" rel="noreferrer noopener">proven results</a>.</p>
<p>“After years of reviewing and reporting on the science behind how people can live longer, healthier lives, we identified the need for more longevity products backed by robust human evidence,” said Dev Heaton, head of Longevity.Technology’s Consumer Division.</p>
<h2 class="wp-block-heading" id="h-why-is-longevity-essential-to-your-healthspan"><strong>Why is LONGEVITY essential to your healthspan?</strong></h2>
<p><a href="https://longevity.technology/store/product/longevity-supplement/?utm_source=lt_lifestyle&utm_medium=launch_article&utm_campaign=longevity_launch_article" target="_blank" rel="noreferrer noopener">Longevity.Technology® LONGEVITY</a> offers a solution for anyone looking to support healthy aging and maximize their healthspan.</p>
<p>Adding this supplement into your daily routine equips your body with tools to fight the effects of aging at the cellular level. It is an investment in long-term wellness designed to help you feel energized, resilient, and ready to face each day confidently.</p>
<p>Longevity.Technology® is a registered trademark of First Longevity Ltd.</p>
<p>[1] <a href="https://www.nature.com/articles/s41580-020-00313-x" target="_blank" rel="noreferrer noopener">https://www.nature.com/articles/s41580-020-00313-x</a><br>[2] <a href="https://www.nature.com/articles/s41598-019-46120-z" target="_blank" rel="noreferrer noopener">https://www.nature.com/articles/s41598-019-46120-z</a><br>[3] <a href="https://physoc.onlinelibrary.wiley.com/doi/epdf/10.1113/JP280825" target="_blank" rel="noreferrer noopener">https://physoc.onlinelibrary.wiley.com/doi/epdf/10.1113/JP280825<br></a>[4] <a href="https://www.sciencedirect.com/science/article/pii/S2352396418303736" target="_blank" rel="noreferrer noopener">https://www.sciencedirect.com/science/article/pii/S2352396418303736</a><br>[5] <a href="https://www.liebertpub.com/doi/10.1089/ars.2012.4901" target="_blank" rel="noreferrer noopener">https://www.liebertpub.com/doi/10.1089/ars.2012.4901</a><br>[6] <a href="https://www.mdpi.com/2304-8158/9/3/340" target="_blank" rel="noreferrer noopener">https://www.mdpi.com/2304-8158/9/3/340</a><br>[7] <a href="https://www.sciencedirect.com/science/article/abs/pii/S0149291818302455" target="_blank" rel="noreferrer noopener">https://www.sciencedirect.com/science/article/abs/pii/S0149291818302455</a><br>[8] <a href="https://www.mdpi.com/1422-0067/22/18/10152" target="_blank" rel="noreferrer noopener">https://www.mdpi.com/1422-0067/22/18/10152</a><br>[9] <a href="https://www.sciencedirect.com/science/article/pii/S0531556522002911" target="_blank" rel="noreferrer noopener">https://www.sciencedirect.com/science/article/pii/S0531556522002911</a><br>[10] <a href="https://www.tandfonline.com/doi/full/10.1080/19390211.2020.1854919#abstract" target="_blank" rel="noreferrer noopener">https://www.tandfonline.com/doi/full/10.1080/19390211.2020.1854919#abstract</a><br>[11] <a href="https://www.nature.com/articles/s43587-022-00322-9" target="_blank" rel="noreferrer noopener">https://www.nature.com/articles/s43587-022-00322-9</a><br>[12] <a href="https://www.aging-us.com/article/101517/pdf" target="_blank" rel="noreferrer noopener">https://www.aging-us.com/article/101517/pdf</a></p>
<p>The post <a href="https://longevity.technology/lifestyle/longevity-technology-debuts-longevity-supplement-a-science-driven-approach-to-healthspan/">Longevity.Technology® debuts LONGEVITY Supplement: A science-driven approach to healthspan</a> appeared first on <a href="https://longevity.technology/lifestyle">Longevity.Technology Lifestyle | Health, Fitness & Technology</a>.</p></div>
Longevity.Technology launches consumer products division
Initial product is a longevity supplement designed to promote healthspan.
Longevity.Technology today announced the launch of its consumer division, which will offer products designed to promote human health and longevity. The company also unveiled its first product, Longevity.Technology® LONGEVITY, a nutritional supplement combining multiple, evidence-based ingredients designed to optimize cellular health.
Leveraging long-standing relationships with leading ingredient suppliers was key to
‘We’re targeting the biggest causes of age-related morbidity and mortality’
Rubedo’s new CEO discusses the potential for senolytics in aging and healthspan as company gears up for clinical trials.
This week, senotherapeutics biopharma Rubedo Life Sciences announced the appointment of Dr Frederick Beddingfield as its new CEO. The biopharma industry veteran, most recently of longevity focused investment firm Apollo Health Ventures, takes over from Rubedo founder Dr Marco Quarta, who becomes the company’s Chief Scientific Officer.
Rubedo is on a mission to keep peop
OneSkin secures $20m Series A to advance skin health solutions
New funding positions biotech to expand research into skin aging and enhance consumer access to peptide-based longevity treatments.
OneSkin has concluded its Series A funding round, amassing a total of $20 million to advance its peptide-based skincare line and expand the brand’s consumer reach. Founded by a team of Brazilian PhD scientists in 2016, OneSkin hit the market with OS-01, a patented peptide shown to prevent senescent cell buildup – identified as a principal factor in skin aging. W
Senolytics Accelerate Reproductive Aging in Aged Mice
<div><p style="text-align: justify;">In a new study, researchers tested the impact of the senolytic drug ABT-263 on the reproductive systems of old female mice. ABT-263 treatment <a href="https://www.nature.com/articles/s41598-024-73828-4">did not rescue age-related changes in hormonal levels, further depleted ovarian reserves, and didn’t improve most of the tested signs of reproductive aging</a> [1].</p>
<h2 style="text-align: justify;"><b>Not created equal</b></h2>
<p style="text-align: justify;">Aging doesn’t seem to affect all organs equally. The female reproductive system appears to be an outlier in aging, as its functionality declines much earlier in life than the rest of the body. Not only does ovarian aging lead to infertility, it is associated with an increased risk of age-related diseases, including cardiovascular diseases, osteoporosis, and mortality [2].</p>
<p style="text-align: justify;">The authors note that one of the issues with aged ovaries is the accumulation of senescent cells. Accumulation of senescent cells can be reversed by using senolytic drugs, such as ABT-263, a drug that has been shown to be able to induce apoptosis, “eliminate senescent cells in various disease models,” and attenuate mice’s ovarian aging when administered early [3]. However, fertility interventions are usually needed at later ages, for which ABT-263 has not been previously tested.</p>
<h2 style="text-align: justify;"><b>Lack of improvement</b></h2>
<p style="text-align: justify;">The researchers treated seven 16-month-old mice with ABT-263 and used another seven 16-month-old mice and six 2-month-old mice as controls. Sixteen months of age is the rough equivalent of a human who is 45 years old, which is around the age of menopause for human females. Mice were treated with ABT-263 for 7 consecutive days, had a 7-day break, and then another 7 days of treatment.</p>
<p style="text-align: justify;">Following the treatment, the researchers examined the mice’s estrus cycles for six consecutive days. The estrus cycle of mice consists of hormonal, cyclical changes that allow for oocytes to mature and be ready for fertilization. It is akin to human females’ monthly cycles; however, the cycles in mice last just 4-5 days.</p>
<p style="text-align: justify;">The researchers observed a difference between the young control group and the two groups with older animals. Older mice, ABT-263-treated and untreated, had irregular estrus cycles, and half of the ABT-263-treated older animals were stuck in the diestrus phase of the cycle. The diestrus phase is the last phase in the cycle, when ovulation has already occurred but the new cycle hasn’t started yet.</p>
<p style="text-align: justify;">Those observations and measurements of levels of specific hormones indicated no significant differences between ABT-263-treated older mice and untreated aged mice, suggesting that ABT-263 treatment didn’t improve estrus cycles in aged mice.</p>
<p style="text-align: justify;">An analysis of ovaries also highlighted a lack of improvements in aged mice despite the ABT-263 treatment. Compared to young mice, aged ABT-263-treated and untreated mice had smaller ovaries with bleeding outside of blood vessels (hematomas). The ovaries of ABT-263-treated aged mice were, as this image shows, even smaller than those of untreated aged mice.</p>
<p><img fetchpriority="high" decoding="async" class="aligncenter wp-image-133328 size-full" src="https://www.lifespan.io/wp-content/uploads/2024/11/Ovarian-aging.png" alt="Ovarian aging" width="1000" height="785" srcset="https://www.lifespan.io/wp-content/uploads/2024/11/Ovarian-aging.png 1000w, https://www.lifespan.io/wp-content/uploads/2024/11/Ovarian-aging-400x314.png 400w, https://www.lifespan.io/wp-content/uploads/2024/11/Ovarian-aging-504x396.png 504w, https://www.lifespan.io/wp-content/uploads/2024/11/Ovarian-aging-256x201.png 256w, https://www.lifespan.io/wp-content/uploads/2024/11/Ovarian-aging-300x236.png 300w, https://www.lifespan.io/wp-content/uploads/2024/11/Ovarian-aging-150x118.png 150w, https://www.lifespan.io/wp-content/uploads/2024/11/Ovarian-aging-480x377.png 480w, https://www.lifespan.io/wp-content/uploads/2024/11/Ovarian-aging-600x471.png 600w, https://www.lifespan.io/wp-content/uploads/2024/11/Ovarian-aging-360x283.png 360w, https://www.lifespan.io/wp-content/uploads/2024/11/Ovarian-aging-262x206.png 262w, https://www.lifespan.io/wp-content/uploads/2024/11/Ovarian-aging-555x436.png 555w" sizes="(max-width: 1000px) 100vw, 1000px"></p>
<h2 style="text-align: justify;"><b>More harm than good</b></h2>
<p style="text-align: justify;">The researchers analyzed the presence of different stages of ovarian follicles. The ovarian follicle is a cellular structure that releases hormones that impact menstrual cycles and releases an egg that can be fertilized. Each female has a set number of follicles at birth. As time passes, those reserves are depleted.</p>
<p style="text-align: justify;">However, it is not only about the quantity of the follicles being reduced with age; the quality also suffers. When the process of activation, development, selection of dominant follicle, and follicle maturation (folliculogenesis) becomes dysregulated due to aging, it leads to poor oocyte quality.</p>
<p style="text-align: justify;">The authors used α-SMA staining to localize follicles, as α-SMA is highly expressed around follicles and the corpus luteum, the remains of the follicle. As expected, young mice had plenty of follicles, and the number was lower in aged mice. The researchers expected the ABT-263 treatment to increase or at least maintain the number of follicles in aged ovaries, but this was not the case. ABT-263 treatment not only didn’t rescue this decrease in follicles in aged mice, it made it worse, suggesting that ABT-263 treatment reduced the ovarian reserves of these mice.</p>
<p style="text-align: justify;">This is in line with measurements of serum AMH, another marker of ovarian reserve. AMH levels were lower in ABT-263-treated mice compared to aged untreated controls. However, the difference was not statistically significant. In light of the other results, this should be tested with a more significant cohort of animals to get a solid answer.</p>
<h2 style="text-align: justify;"><b>Hallmarks of ovarian aging</b></h2>
<p style="text-align: justify;">A reduced number of follicles is not the only aspect of ovarian aging. There is also the formation of multinucleated giant cells (MGCs), ovarian fibrosis, and a higher expression of γ-H2AX, a marker of DNA double-strand damage response in granulosa cells and ovarian stromal cells, which are different cell types that reside in the ovary. The number of ovarian stromal cells that expressed γ-H2AX wasn’t significantly different between the groups of mice.</p>
<p style="text-align: justify;">DNA double-strand damage response is a process that drives apoptosis and senescence. However, the researchers noted a difference in apoptosis, with aged groups (ABT-263 treated and untreated) showing more apoptosis than the young mice, suggesting that cell apoptosis is independent of DNA damage in ovarian stromal cells. In this study, the researchers observed the presence of MGCs in the ovaries of aged mice, and ABT-263 treatment didn’t prevent MGCs formation in aged mice.</p>
<p style="text-align: justify;">Despite the lack of positive results on multiple aspects of ovarian aging, there were also some positive effects of ABT-263 treatment; for example, age-related fibrosis in ovarian tissue was mitigated by ABT-263. However, this reduced fibrosis cannot prevent ABT-263’s negative impact on follicles and acceleration of ovarian aging in aged mice.</p>
<p style="text-align: justify;">ABT-263 treatment also positively impacted the expression of genes impacting the production of steroid hormones (steroidogenic genes). However, almost all those changes were statistically insignificant. Increasing the number of animals in future experiments might show more conclusive results.</p>
<h2 style="text-align: justify;"><b>Context dependence</b></h2>
<p style="text-align: justify;">While this study was performed on a small number of animals, the results suggest that some interventions might be context-specific. In this case, a senolytic previously shown to be successful in attenuating mice’s ovarian aging when administered early doesn’t have the same effect on older mice. The mechanism behind these differences requires further investigation. Still, these results highlight the importance of testing the same drug or intervention in different contexts, such as different ages, and the importance of early intervention in preserving female fertility.</p>
<p style="text-align: justify;">While this research was done in rodents and still needs to be tested in humans, the authors suggest that “ABT-263 treatment accelerated the depletion of ovarian follicles in aged mice, suggesting that the administration of senolytic drugs in aged women may expedite the process of reproductive aging.”</p>
<p style="text-align: justify;">The researchers tested many phenotypes associated with reproductive aging and the impact of ABT-263 treatment on those phenotypes. However, the ultimate test for reproduction is whether an animal can produce healthy offspring. This, however, was not tested in this study, and future research should address this question.</p>
<div class="textwidget"><div class="sep-2"></div>
<div class="life-highlight-box lhbox-has-zoom-yes l-hbox-size-large l-hbox-edges-square" style="background-color: #cef0f5;"><div class="l-hbox-lower"><div class="l-hbox-lower-desc" style="color:#000;">We would like to ask you a small favor. <strong>We are a non-profit foundation</strong>, and unlike some other organizations, we have no shareholders and no products to sell you. <strong>All our news and educational content is free</strong> for everyone to read, but it does mean that we rely on the help of people like you. Every contribution, no matter if it’s big or small, <strong>supports independent journalism</strong> and sustains our future. </div><style>.rb--2fc2e1d23f5a19 a {background-color:#1e4fba;}.rb--2fc2e1d23f5a19 a:hover {background-color:#79bcf0;}</style><div class="l-hbox-lower-cta rb--2fc2e1d23f5a19"><a href="https://www.lifespan.io/how-you-can-help/" target="_self" rel="noopener">Yes I will donate❤️</a></div></div></div>
</div>
<h2 style="text-align: justify;"><b>Literature</b></h2>
<p style="text-align: justify;">[1] Xia, X., Yang, Y., Liu, P., Chen, L., Dai, X., Xue, P., & Wang, Y. (2024). The senolytic drug ABT-263 accelerates ovarian aging in older female mice. Scientific reports, 14(1), 23178.</p>
<p style="text-align: justify;">[2] Christensen, M. W., Kesmodel, U. S., Christensen, K., Kirkegaard, K., & Ingerslev, H. J. (2020). Early ovarian ageing: is a low number of oocytes harvested in young women associated with an earlier and increased risk of age-related diseases?. Human reproduction (Oxford, England), 35(10), 2375–2390.</p>
<p style="text-align: justify;">[3] Yan, H., Miranda, E. A. D., Jin, S., Wilson, F., An, K., Godbee, B., Zheng, X., Brau-Rodríguez, A. R., & Lei, L. (2024). Primary oocytes with cellular senescence features are involved in ovarian aging in mice. Scientific reports, 14(1), 13606.</p>
<div id="playht-shortcode" data-shortcode='
<div
id="playht-iframe-wrapper"
style="display:flex; max-height:"90px"; justify-content:center">
<iframe
allowfullscreen=""
frameborder="0"
scrolling="no"
class="playht-iframe-player"
data-appId="E9FaMfn-qe"
article-url="https://www.lifespan.io/?p=133322"
data-voice="en-US-CoraNeural"
src="https://play.ht/embed/?article_url=https://www.lifespan.io/?p=133322&voice=en-US-CoraNeural&config={"width":""100%"","height":""90px"","alignment":"center","title":"Audio","message":"Hello","download_text_button":"Download"}"
width=""100%""
height=""90px""
style="max-height:"90px"">
</iframe>
</div>'></div></div>
AI drug discovery firm inks investment and collaboration deal with NVIDIA
Genesis to work with NVIDIA to optimize its neural network architectures around 3D geometric data of proteins and drug-like molecules.
Artificial intelligence-powered drug discovery company Genesis Therapeutics has announced a new equity investment and strategic collaboration with tech giant NVIDIA, aiming to push forward advancements in its AI platform. The equity contribution comes from NVentures, the venture capital division of NVIDIA, which also took part in the last year’s oversubscribe